Relaxin improves TNF-α-induced endothelial dysfunction: The role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling

Cardiovascular Research

Volumn 95, Issue 1, 2012, Pages 97-107

  Dschietzig, Thomas ^a   Brecht, Anna ^b   Bartsch, Cornelia ^b   Baumann, Gert ^b   Stangl, Karl ^b   Alexiou, Konstantin ^c  

^a IMMUNDIAGNOSTIK AG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Herzzentrum Brandenburg in Bernau   (Germany)

Author keywords

Endothelial dysfunction; eNOS; Glucocorticoid receptor; PI3 kinase; Relaxin

Indexed keywords

3 NITROTYROSINE; 4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; ARGINASE; ARGINASE 2; CCAAT ENHANCER BINDING PROTEIN BETA; COPPER ZINC SUPEROXIDE DISMUTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GLUCOCORTICOID RECEPTOR; I KAPPA B; LONAPRISAN; MIFEPRISTONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RELAXIN; SUPEROXIDE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; ARGINASE; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; ENDOTHELIUM, VASCULAR; MALE; NADPH OXIDASE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; RATS, WISTAR; RECEPTORS, GLUCOCORTICOID; RELAXIN; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862876898     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs149     Document Type: Article

References (44)

1. Bathgate RA, Ivell R, Sanborn BM, Sherwood OD, Summers RJ. International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol Rev 2006;58:7-31.
2. Halls ML, Bathgate RA, Summers RJ. Comparison of signaling pathways activated by the relaxin family peptide receptors, RXFP1 and RXFP2, using reporter genes. J Pharmacol Exp Ther 2007;320:281-290.
3. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res 2003;92:32-40.
4. Dschietzig T, Bartsch C, Stangl V, Baumann G, Stangl K. Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist. FASEB J 2004;18:1536-1538.
5. Samuel CS, Hewitson TD, Unemori EN, Tang ML. Drugs of the future: the hormone relaxin. Cell Mol Life Sci 2007;64:1539-1557.
6. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005;25:29-38.
7. Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 2006;99:69-77.
8. Münzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008;40:180-196.
9. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol 1992;262:854-861.
10. Bani-Sacchi T, Bigazzi M, Bani D, Mannaioni PF, Masini E. Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 1995; 116:1589-1594.
11. Brecht A, Bartsch C, Baumann G, Stangl K, Dschietzig T. Relaxin inhibits early steps in vascular inflammation. Regul Pept 2011;166:76-82.
12. Nistri S, Chiappini L, Sassoli C, Bani D. Relaxin inhibits lipopolysaccharide-induced adhesion of neutrophils to coronary endothelial cells by a nitric oxide-mediated mechanism. FASEB J 2003;17:2109-2111.
13. Lorenz M, Wilck N, Meiners S, Ludwig A, Baumann G, Stangl K et al. Proteasome inhibition prevents experimentally-induced endothelial dysfunction. Life Sci 2009;84: 929-934.
14. Bourgeois S, Pfahl M, Baulieu EE. DNA binding properties of glucocorticosteroid receptors bound to the steroid antagonist RU-486. EMBO J 1984;3:751-755.
15. Miner JN, Tyree C, Hu J, Berger E, Marschke K, Nakane M et al. A nonsteroidal glucocorticoid receptor antagonist. Mol Endocrinol 2003;17:117-127.
16. Fuhrmann U, Hess-Stumpp H, Cleve A, Neef G, Schwede W, Hoffmann J et al. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem 2000;43:5010-5016.
17. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-7689.
18. Whitson EL, Bugni TS, Chockalingam PS, Concepcion GP, Harper MK, Min H et al. Spheciosterol sulfates, PKCzeta inhibitors from a philippine sponge Spheciospongia sp. J Nat Prod 2008;71:1213-1217.
19. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB et al. Pharmacological characterization of A-127722: an orally active and highly potent ETAselective receptor antagonist. J Pharmacol Exp Ther 1996;276:473-481.
20. von Geldern TW, Tasker AS, Sorensen BK, Winn M, Szczepankiewicz BG, Dixon DB et al. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity. J Med Chem 1999;42:3668-3678.
21. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJ et al. 1400Wis a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 1997;272:4959-4963.
22. Ichihara A, Inscho EW, Imig JD, Navar LG. Neuronal nitric oxide synthase modulates rat renal microvascular function. Am J Physiol 1998;274:516-524.
23. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L et al. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 2004;110: 3708-3714.
24. Marikovsky M, Ziv V, Nevo N, Harris-Cerruti C, Mahler O. Cu/Zn superoxide dismutase plays important role in immune response. J Immunol 2003;170:2993-3001.
25. Brunner F, Stessel H, Graier WF. The effects of intracellular Ca2+ concentration and hypoxia on basal endothelin-1 secretion by cultured porcine aortic endothelial cells. Agents Actions Suppl 1995;45:269-273.
26. Fernandes DC, Wosniak J Jr, Pescatore LA, Bertoline MA, Liberman M, Laurindo FR et al. Analysis of DHE-derived oxidation products by HPLC in the assessment of superoxide production and NADPH oxidase activity in vascular systems. Am J Physiol Cell Physiol 2007;292:413-422.
27. Chang CI, Zoghi B, Liao JC, Kuo L. The involvement of tyrosine kinases, cyclic AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated arginase I induction in macrophages: its implications in IL-13-inhibited nitric oxide production. J Immunol 2000;165:2134-2141.
28. Afonso V, Santos G, Collin P, Khatib AM, Mitrovic DR, Lomri N et al. Tumor necrosis factor-alpha down-regulates human Cu/Zn superoxide dismutase 1 promoter via JNK/AP-1 signaling pathway. Free Radic Biol Med 2006;41:709-721.
29. Haber PL, Osborn TG, Moore TL. Antinuclear antibody in juvenile rheumatoid arthritis sera reacts with 50-40 kDa antigen(s) found in HeLa nuclear extracts. J Rheumatol 1989;16:949-954.
30. Milani P, Gagliardi S, Cova E, Cereda C. SOD1 transcriptional and posttranscriptional regulation and its potential implications in ALS. Neurol Res Int 2011;2011:458427.
31. Wyszomierski SL, Rosen JM. Cooperative effects of STAT5 (signal transducer and activator of transcription 5) and C/EBPbeta (CCAAT/enhancer- binding protein-beta) on beta-casein gene transcription are mediated by the glucocorticoid receptor. Mol Endocrinol 2001;15:228-240.
32. Chen X, Andresen1 BT, Hill M, Zhang J, Booth F, Zhang C. Role of reactive oxygen species in tumor necrosis factor-alpha induced endothelial dysfunction. Curr Hypertens Rev 2008;4:245-255.
33. Förstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010;459:923-939.
34. Dschietzig T, Bartsch C, Baumann G, Stangl K. RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway. Regul Pept 2009;154:77-84.
35. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 2007;42:271-279.
36. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000;20:83-88.
37. Dschietzig T, Bartsch C, Wessler S, Baumann G, Stangl K. Autoregulation of human relaxin-2 gene expression critically involves relaxin and glucocorticoid receptor binding to glucocorticoid response half-sites in the relaxin-2 promoter. Regul Pept 2009;155:163-173.
38. Connaughton S, Chowdhury F, Attia RR, Song S, Yi Z, Elam MB et al. Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by glucocorticoids and insulin. Mol Cell Endocrinol 2010;315:159-166.
39. Horowitz S, Binion DG, Nelson VM, Kanaa Y, Javadi P, Lazarova Z et al. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2007;292:1323-1336.
40. Anwar KN, Fazal F, Malik AB, Rahman A. RhoA/Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of I kappa B kinase beta and phosphorylation of RelA/p65. J Immunol 2004;173:6965-6972.
41. DuranteW, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007;34:906-911.
42. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998;94:557-572.
43. Kawanabe Y, Nauli SM. Endothelin. Cell Mol Life Sci 2011;68:195-203.
44. Bani D. Relaxin as a natural agent for vascular health. Vasc Health Risk Manag 2008;4: 515-524.